France· FR:61116813
ENFLONSIA 105 mg, solution injectable en seringue préremplie
A clesrovimab product containing clesrovimab, registered in France by MERCK SHARP & DOHME (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Clesrovimab is registered in 11 of 19 countries.
Countries holding a registration under ATC J06BD10 (clesrovimab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Clesrovimab · ATC J06BD10
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CLESROVIMAB
- Manufacturer
- MERCK SHARP & DOHME (PAYS-BAS)
- Country
- France (FR)
- ATC code
- J06BD10
- ATC class
- Clesrovimab
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009303286131 seringue préremplie en verre de 0,7 mL + 1 aiguilleEUR 401.8
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Clesrovimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEnflonsiaMerck Sharp & Dohme B.V.
- IrelandEnflonsia 105 mg solution for injection in pre-filled syringeMerck Sharp & Dohme BV,
- NetherlandsEnflonsia 105 mg oplossing voor injectie in een voorgevulde spuitMerck Sharp & Dohme B.V.
- CzechiaENFLONSIAMerck Sharp & Dohme B.V., Haarlem
- SwitzerlandEnflonsia
- IcelandEnflonsiaMerck Sharp & Dohme B.V.*
- NorwayEnflonsiaMerck Sharp & Dohme B.V.
- PolandEnflonsiaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enflonsia
- Liechtenstein · Enflonsia
- Norway · Enflonsia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/88f0ab70-eed7-4dd5-8be3-7295dbc4e4b2 GET /v1/drugs/88f0ab70-eed7-4dd5-8be3-7295dbc4e4b2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61116813",
"date_amm": "2026-04-15",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/25/1984",
"substance": "CLESROVIMAB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intramusculaire",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about clesrovimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.